Programme

Thursday, 23rd June 2016
Citylabs, Nelson St, Manchester M13 9NQ

The official programme of EASDec starts

18.30 – 20.00 Opening ceremony with light refreshments

Friday, 24th June 2016
Rooms C2, C8 & C15, Renold Building, University of Manchester

08.30 Registration at the trade exhibition
08.50 Introduction and Welcome
   Professor Simon Harding, President of EASDec
09.00 Session 1
   Treatment of diabetic macular oedema
   Chair: Professor Massimo Porta and Mrs Yvonne D'Souza

09.15 Keynote speaker: Professor Albert Augustin, Germany
   The EARLY Study and the use of steroids in the treatment of diabetic macular oedema
   Introduced by Mrs Yvonne D'Souza

09.30 S Subramani (UK)
   Intravitreal ranibizumab for diabetic macular oedema - a retrospective review of 12 month follow up data at The Manchester Royal Eye Hospital (MREH), UK

09.45 SP Kelly (UK)
   Real-world outcomes with ranibizumab treatment in diabetic macular oedema patients with poor baseline visual acuity: 1-year results from the LUMINOUS™ study

“Every time you liberate a woman, you liberate a man” - Emmeline Pankhurst
10.00 The winner of the Professor Anne Katrin Sjolie Prize for the best abstract from a trainee: BS Gerendas (Austria)
Prognostic factors in the treatment of diabetic macular edema (DME) using aflibercept, ranibizumab and bevacizumab (DRCR.net protocol T)
*Introduced by Professor Simon Harding*

10.15 **Keynote speaker: Professor Paul Bishop, Manchester, UK**
Metabolomics and metallomics provide novel insights into the molecular pathology of diabetic retinopathy
*Introduced by Professor Massimo Porta*

10.30 **Coffee and tea at the trade exhibition**

11.15 **Session 2**
**Diabetic retinopathy screening and visual function**
*Chaired by Dr Deborah Broadbent and Dr Naveed Younis*

11.15 **H Thorning-Schmidt (Denmark)**
Nurse-led eye screening in a specialist diabetes clinic is cost-effective and has shown a reduction in visual impairment and blindness

11.30 **IM Stratton (UK)**
Retinopathy in children with diabetes: when should they be screened?

11.45 **C Sampson (UK)**
Microcosting diabetic eye screening: estimation of personal expense, attendance and health care resource use

12.00 **SJ Aldington (UK)**
Providing the international Test and Training (iTAT) for quality assurance and training support for retinopathy screening through ‘Seeing is Believing’ projects

12.15 **O Durando (Italy)**
Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial.

12.30 **A Raj (UK)**
Oscillatory potential: A more sensitive marker for diabetic maculopathy progression?

“There is nothing so fatal to character as half finished tasks” • David Lloyd George
12.45  **Lunch at the exhibition (poster presenters are priority)**

1.15  **Session 3**  
**Poster Session**

1.15  *Poster presenters at poster as moderators will visit*  
2.15  *Tea/coffee served as poster presenters circulate*

**Laboratory Science Poster Presentations**  
**Moderated by Professors Rafael Simo and Ingeborg Klaassen**

1.  I Ali (UK)  
Capsulotomy induced retinal degeneration in Ins2Akita mice is protected by Wnt inhibition

2.  R Schlingemann (The Netherlands)  
PLVAP is required for angiogenesis in vivo

3.  A Van der Wijk (The Netherlands)  
The development of the blood-retinal barrier as an inverse model of blood-retinal barrier loss in diseases of the retina

4.  E Szalai (Hungary)  
Early corneal cellular and nerve fibre pathology in young patients with type 1 diabetes mellitus identified using corneal confocal microscopy

5.  AM Valverde (Spain)  
Inhibition of protein tyrosine phosphatase 1B protects against inflammation-induced gliosis in the retina

6.  M Ullrich (Austria)  
Exploring the pathobiology of diabetic macular oedema by post-mortem immunohistochemistry

**Epidemiology, Risk factors and Visual function /QoL Poster Presentations**  
**Moderated by Professors Tunde Peto and Massimo Porta**

7.  M Dutra Medeiros (Portugal)  
First diabetic retinopathy prevalence study in Portugal: RETINODIAB Study—Evaluation of the screening programme for Lisbon and Tagus Valley region

---

“I think you never stop learning”  *Norman Foster*
8. JF Raposo (Portugal)
   First incidence and progression study for diabetic retinopathy in Portugal, the RETINODIAB Study evaluation of the screening program for Lisbon region

9. I Derkac (Lithuania)
   The relevance of serum apolipoprotein B, apolipoprotein A1 and its ratio to the severity of diabetic retinopathy in type 1 diabetes mellitus

10. N Gahir (UK)
    Diabetic Retinopathy after initiating continuous subcutaneous insulin infusion (insulin pump)

11. V Schreur (The Netherlands)
    Risk factors for diabetic retinopathy in type 1 diabetes mellitus patients with poor glycaemic control

12. MI Lopez Galvez (Spain)
    Quality of life in patients with diabetic macular oedema and moderate to severe vision loss treated with ranibizumab in clinical practice

Screening and Automated Grading Poster Presentations
Moderated by Professors Steve Aldington and Simon Harding

13. SP Harding (UK)
    10-year observational study of patient related outcomes during expansion to full population coverage of a systematic diabetes eye care programme – the Liverpool Diabetic Eye Study

14. A van der Heijden (The Netherlands)
    Validation of an algorithm to predict the risk of sight threatening retinopathy in a multi-ethnic patient group treated in a secondary care setting

15. S Parvizi (UK)
    Can we adopt a pragmatic approach to arterial embolus referrals from the diabetic eye screening programme?

16. RBR Moreton (UK)
    Factors determining patient uptake of diabetic retinopathy screening in Oxfordshire

17. D Palethorpe (UK)
    Evaluation of clinical and treatment outcomes of patients referred from the NHS Diabetic Eye Screening Programme

“I am a simple man, and I use simple things” • LS Lowrie
18. A Brown (UK)
   Characteristics and outcome of referable diabetic maculopathy

19. A Stewart (UK)
   The characteristics of patients referred by an English Diabetic Eye Screening Programme

20. A Brown (UK)
   The characteristics of patients who do not attend their hospital eye clinic appointment following referral with diabetic retinopathy

21. SL Blindbæk (Denmark)
   Predictive value of retinal venous loops in the screening for proliferative diabetic retinopathy

22. R Thomas (UK)
   Prevalence of diabetic retinopathy in children and young persons with type 1 diabetes within the Diabetic Retinopathy Screening Service for Wales (DRSSW)

23. C Sampson (UK)
   Health-related quality of life of people attending screening for diabetic retinopathy within a trial setting

24. IM Stratton (UK)
   When does retinopathy have an impact on visual acuity?

25. N Palarie (Moldova)
   First diabetic eye screening program in Moldova - 2 years results

26. S Patra (UK)
   The risk of clinical harm due to delayed follow-up in patients with sight threatening diabetic retinopathy

27. A Wang (UK)
   Building a dynamic functional clinical data warehouse for personalised health care - lessons from the Individualised Screening for Diabetic Retinopathy study

28. RT Staff (UK)
   Quality assurance in diabetic retinal screening in South Africa: a baseline and follow-up study

29. L Toth (UK)
   Visual outcomes in patients attending the surveillance and slit lamp clinic of the Tower Hamlets Diabetic Eye Screening Programme

_Every dogma has its day • Anthony Burgess_
30. C Thetford (UK)
Comparing health professionals’ and patient perspectives of individualised screening intervals for diabetic retinopathy screening

31. ML Ribeiro (Portugal)
Added value of an automated analysis system in the context of diabetic retinopathy screening

32. M Hansen (Denmark)
Automated detection of diabetic retinopathy in three European populations

**Imaging Poster Presentations**

Moderated by Professor Eduardo Midena and Mr Stephen Charles

33. E Midena (Italy)
Hyper reflective retinal spots in diabetic eyes: the validation approach

34. S Vujosevic (Italy)
Diabetic macular edema with subfoveal neuroretinal detachment: specific morphologic and functional entity

35. P Stanga (UK)
Vitreous segmentation of ocular coherence tomography angiography of the posterior pole and mid-periphery in diabetic retinopathy

36. L Tomasso (Italy)
Dynamic functionality and static changes of retinal vessels in eyes with diabetic macular edema

37. L Benatti (Italy)
Impact of intravitreal ranibizumab on vessel functionality in patients with diabetic macular edema

38. IP Marques (Portugal)
Methods for quantification of retinal microvascular density in Cirrus AngioPlex OCT angiography (OCTA) Images

39. MV Cicinelli (Italy)
Morpho-functional evaluation of diabetic eyes without diabetic retinopathy

“One can never be sure of the end, only the means, so we must ensure the means are good” ~ Marghanita Laski
40. T Lee Torp (Denmark)
Retinal vascular fractal dimension as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy

41. E Corbelli (Italy)
Assessment of foveal avascular zone in diabetic retinopathy by Optical Coherence Tomography Angiography and correlation analysis with peripheral perfusion index

Clinical Management Poster Presentations
Moderated by Professors Reinier Schlingemann and Peter Scanlon

42. E Tsamis (UK)
Ultra wide-field fundus fluorescein angiography – guided Pascal laser targeted retinal photocoagulation as a first treatment option for the management of proliferative and exudative vascular retinal disorders

43. K Chwiejczak (UK)
Barely visible yellow Pascal® laser with or without endpoint management* in treating proliferative diabetic retinopathy and diabetic macular oedema: safety and efficacy study

44. F Bandello (Italy)
Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy

45. E Doğan (Turkey)
Short-term outcomes of intravitreal aflibercept on intraocular pressure

46. D Hodzic-Hadzibegovic (Denmark)
Nonresponders in a group of unselected diabetes patients treated with ranibizumab for diabetic macular oedema

47. K Jasani (UK)
12 months outcomes of patients with diabetic macula oedema treated with Ranibizumab in a real world DGH setting presented using a novel visual method of clinical outcomes presentation.

“The only real security for social well-being is the free exercise of men’s mind” – Harold Laski
48. MA Costa (Portugal)
OCT retinal thickness response after first intravitreal injection is a predictor of visual acuity response to anti-VEGF treatment of DME

49. P Scanlon (UK)
Real world outcomes of VEGF inhibitor injection clinics for centre involving diabetic macular oedema

50. B Dupas (France)
Indocyanine green-guided targeted photoagulation of macroaneurysms in macular edema: a pilot study

51. A Pareja-Rios (Spain)
Clinical management of diabetic macular edema by retina specialists in clinical practice in Spain: OBSERVAR Study

52. F Zacharaki (UK)
Intravitreal ranibizumab for the treatment of diabetic macular oedema: real-life 12 month results

53. S Dikci (Turkey)
Results of intravitreal dexamethasone implant (Ozurdex®) in cases with resistant diabetic macular edema and hard exudates on the macular centre

54. G Querques (Italy)
Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France

55. A Erginay (France)
Efficacy results of 0.2 µg/day fluocinolone acetonide implant (FAc) in DME vitrectomised patients

56. T Peto (UK)
Subgroup analysis of the FAME trial assessing the impact of prior therapies on vision outcomes with ILUVIEN® (fluocinolone acetonide [FAc]) implant

57. S Ba-Ali (Denmark)
Effect of dexamethasone intravitreal implant, Ozurdex®, on diabetic macular oedema during pregnancy

“My object has been, first to discover correct principles and then to suggest their practical development” • James Prescott Joule
2.45 **Session 4**
*Experimental Science*
*Chaired by Professors Thomas Gardner and Reinier Schlingemann*

2.45 **C Hernández (Spain)**
Mediators between reactive gliosis and vascular leakage in diabetic retinopathy: a proteomic approach using human retinas

3.00 **I Klaassen (The Netherlands)**
PLVAP regulates angiogenesis through VEGFR2

3.15 **Al Arroba (Spain)**
Modulation of microglia polarization dynamics by a sp2-iminosugar derivative during diabetic retinopathy in db/db mice

3.30 **A Mazzeo (Italy)**
Different miRNA patterns in extracellular vesicles from diabetic and healthy subjects

3.45 **JR Hombrebueno (Northern Ireland)**
Targeting STAT3 for the treatment of proliferative diabetic retinopathy

4.00 **Professor Rafael Simó (Spain)**
The EuroCondor trial and beyond

4.15 **Eva Kohner Lecture**
Professor Thomas W. Gardner, Professor of Ophthalmology and Visual Sciences and Molecular & Integrative Physiology, Ann Arbor, Michigan, USA
*Introduced by Professor Rafael Simó*

5.00 **Annual General Meeting**
*Moderator: Professor Reinier Schlingemann*

7.00- **Conference Reception and Dinner**
11.30 *Dancing to Blue Note Mitch and The Red Hot Jacks (jazz, swing and jive)*
*Museum of Science and Industry, Castlefield, M3 4FP*

“A belief is not merely an idea the mind possesses; it is an idea that possesses the mind” • Robert Bolt
08.30  Registration at the trade exhibition

09.00  Session 5  
**Imaging and New Technologies**  
*Chair by Professors Paulo Stanga and Simon Harding*

9.00  **M Bhaskaranand (USA)**  
Study of safety and effectiveness of automated diabetic retinopathy screening system on a large set of consecutive patient visits

9.15  **S Philip (UK)**  
Automated microaneurysm counts in the region temporal to the fovea associated with the severity of diabetic retinopathy

9.30  **S Al-Bander (UK)**  
Automatic detection of fovea and optic disc using deep neural networks

9.45  **A Papayannis (UK)**  
Ultra-wide field swept-source optical coherence tomography angiography (UWF SS OCT-A) in diabetic retinopathy

10.00  **M Soares (Portugal)**  
Comparison of Diabetic Retinopathy Classification using Fluorescein Angiography and Optical Coherence Tomography Angiography

10.15  **AR Santos (Portugal)**  
OCT predictors for BCVA response to intravitreal anti-VEGF treatment in eyes with diabetic macular edema

10.30  **Coffee and tea at the trade exhibition: clinical poster challenges**

“An educated man is one who knows a lot but says nothing about it” — Dame Gracie Fields
11.15 **Keynote lecture: Professor Andrew J. Boulton, Manchester**
Type 2 diabetes – the 21st Century Epidemic
*Introduced by Professor Massimo Porta*

11.45 **Session 6**
**Mini Symposium of OCT**
*Chaired by Mr Stephen Charles and Professor Andrew Boulton*

11.45 **J Cunha-Vaz (Portugal)**
Automated analysis of retinal extracellular space using Optical Coherence Tomography. A non-invasive indirect identification of the sites of alterations of the Blood-Retinal Barrier

12.00 **E De Clerck (the Netherlands)**
Glucose metabolism status is associated with changes in macular thickness

12.15 **Debate:**
**OCT change in early diabetic maculopathy: thicker or thinner?**
*Moderated by Professor Simon Harding*

12.15 In favour of thinning being the early sign of neurodegenerative pathway:
Jakob Grauslund, Denmark

12.30 In favour of thickening being an early sign of neurodegenerative pathway:
Paulo Stanga, UK

12.45 Preliminary discussion points: Can we see distinct phenotypes? What happens with the choroid?

13.00 **Best poster prize ceremony and closing remarks**
*Professor Simon Harding, President of EASDec*

“There’s some people on the pitch... they think it’s all over... it is now” - •
*Kenneth Wolstenholme*